Researchers at Emory’s Center for Translational Social Neuroscience (CTSN) are focusing on prairie voles as a new model to screen the effectiveness of drugs to treat autism.
They are starting with D-cycloserine, a drug Emory researchers have shown enhances behavioral therapy for phobias and also promotes pair bonding among prairie voles. Giving female voles D-cycloserine, which is thought to facilitate learning and memory, can encourage them to bond with a new male more quickly than usual. The findings will be published in Biological Psychiatry.
“The prairie vole model has enabled us to learn about complex neural pathways in social areas of the brain,” says Larry Young (at left) director of the CTSN. “We believe these insights will be useful in identifying drugs that enhance social cognition and learning. Drugs with these properties, particularly when combined with behavioral therapies, may be beneficial in the treatment of autism spectrum disorders.”
The prairie vole is one of the few species in nature that is monogamous and that creates deep social bonds while mating. The basic mechanisms of voles’ and humans’ social learning are similar enough that the learning that occurs during voles’ pair bonding can model complex human social interactions. Young and his colleagues have used voles to show the importance for social interactions of hormones such as oxytocin, which has also been proposed as a treatment for autism spectrum disorders.
The first author of the paper is Emory graduate student Meera Modi. She showed that D-cycloserine promotes pair bonding in prairie voles when it is injected peripherally. By infusing the drug directly into specific regions of the brain, she also showed the importance of two regions linked to social learning and reward, the nucleus accumbens and amygdala.
"We think D-cycloserine interacts with the brain's social information processing circuits to enhance the natural learning processes that occur there,” Modi says.
Emory researchers have shown D-cycloserine can be used to treat psychiatric diseases such as phobias and social anxiety. It is now in clinical trials for treatment of post-traumatic stress disorder. D-cycloserine is thought to enhance learning by acting on receptors for the neurotransmitter glutamate.
Autism spectrum disorders affect one in 110 children in the United States, according to the Centers for Disease Control and Prevention. Currently there are no drugs that specifically target social deficits found in individuals with autism, Young notes. Most drugs now prescribed for individuals with autism were originally developed for other disorders such as depression or schizophrenia.
The research was supported by a fellowship from Autism Speaks and by the National Institutes of Health.
The chemical basis of love
How early nurturing affects adult love
Mapping the social brain
Anxious kids confuse mad and sad